If you or someone you love has Parkinson's, you've probably run into a strange fact about how it's treated: the best medicine, levodopa, was discovered more than 50 years ago, and it's still the best medicine we have. Everything since has really just been about delivering it better, smoothing out the times it wears off, and covering what it doesn't fix. Between August 2024 and February 2025, the FDA approved three new medicines, more in six months than in the several years before that. But every single one of them fits that same pattern. Not one of them actually slows the disease down.
More than 1 million Americans live with Parkinson's, and about 90,000 more are diagnosed every year. This article covers what treatment looks like today, why slowing the disease has been so hard to do, what researchers are testing right now, and where clinical trials fit in.
Looking for treatment options for Parkinson's Disease?
Browse open parkinson's clinical trials near you! We'll handle the follow-up.
What Parkinson's treatment includes today
Levodopa, still the foundation. Levodopa is converted to dopamine in the brain, replacing what the dying cells no longer make. It works remarkably well for years. Its weakness is timing: as the disease advances, doses wear off between pills ("off" periods) and can cause involuntary movements ("dyskinesia"). Much of modern treatment is engineering around that.
The 2024 to 2025 approvals. Crexont (August 2024) is an extended release levodopa capsule designed for fewer daily doses. Vyalev (October 2024) is a 24 hour pump that delivers levodopa continuously under the skin, for people with advanced disease whose pills no longer give steady control. Onapgo (February 2025) is a similar pump for apomorphine, a fast acting dopamine medicine. A fourth medicine, tavapadon, a once daily pill that works on a different set of dopamine receptors than existing drugs, was submitted to the FDA in September 2025 and is under review as of this writing. It is not yet approved.
Other medicines. Dopamine agonists, MAO-B inhibitors, and COMT inhibitors extend or mimic dopamine's effect and are used alone early or alongside levodopa later. In March 2026 the FDA added a warning to all levodopa products about vitamin B6 deficiency, after reports of seizures in people taking very high doses, a reminder that even 50 year old drugs still teach us things.
Deep brain stimulation. DBS implants electrodes in movement centers of the brain and is the main option when medicines stop giving steady control. Five year results published in 2025 show lasting improvement in movement and reduced medication needs. A newer adaptive version reads brain signals and adjusts stimulation in real time; early data suggest about 35 percent more motor improvement than conventional DBS.
Exercise, prescribed. Regular vigorous exercise improves movement, balance, and mood, and it has the strongest evidence of any intervention for possibly slowing progression. Neurologists now recommend it as treatment, not just advice.
What researchers are studying now
Slowing the disease: alpha synuclein. The misfolded protein at the root of Parkinson's is the main target researchers are going after. Roche's prasinezumab, an antibody against alpha synuclein, showed a hint of benefit in earlier trials and is now in Phase 3; the IV prasinezumab study is recruiting on our platform. Drugs targeting the LRRK2 gene, the most common genetic cause, are being tested in both genetic and non genetic Parkinson's.
Replacing lost cells. Bemdaneprocel, lab grown dopamine neurons made from stem cells and implanted into the brain, became the first cell therapy for Parkinson's to reach Phase 3 when the first patient was treated in September 2025; that Phase 3 study is recruiting. A different approach, grafting a patient's own nerve tissue into the affected part of the brain, is also being tested on our platform. Both require brain surgery and careful screening, and results take years.
What did not work. GLP-1 drugs like exenatide showed early promise, but the Phase 3 exenatide trial published in 2025 found no real benefit on how the disease progressed. Several trials of a handful of GLP-1 medicines have been run so far, and only one showed a real advantage over placebo. The Parkinson's Foundation says plainly that these drugs aren't a proven Parkinson's treatment. A semaglutide trial in Parkinson's finished enrolling people in 2024, and results are expected soon.
Exercise as a drug, with a dose. The Exercise Neuroprotection study is testing whether high intensity exercise protects brain cells, and Slow-SPEED is testing exercise dosage in people with early, or even pre diagnosis, Parkinson's. A digital music based walking program is testing a very different way to keep people moving.
Catching it before the tremor. A 2023 test can detect misfolded alpha synuclein in spinal fluid. Now researchers are testing easier ways to catch it: colon tissue biopsy and colonoscopy based detection, since the protein actually shows up in the gut years before it reaches the brain. The Gut Brain in Parkinson's Consortium is studying that gut brain connection directly, and PPMI, one of the largest Parkinson's studies in the world, keeps following people for years to map out how the disease unfolds over time.
The symptoms that are not tremor. Psilocybin therapy for depression in Parkinson's, tenapanor for the constipation that affects most patients, and a home stimulation device for motor symptoms all address the everyday problems that tremor focused medicines leave behind.
Why Parkinson's research takes time
The half gone problem. By the time someone is diagnosed, 60 to 80 percent of their dopamine producing cells may already be dead. A drug meant to slow the disease doesn't have much left to work with at that point. That's why so much effort now goes into catching Parkinson's earlier, back in the years when constipation, a lost sense of smell, and sleep changes show up first, since that's when a disease slowing drug would actually matter most. Finding better tests for that early window is its own research problem.
The measurement problem. Parkinson's progresses slowly and unevenly, and doctors score it through an exam, not a blood test. Levodopa also hides how the disease is really progressing underneath, so trials testing disease slowing drugs have to either enroll people who aren't on medicine yet, or find some way to see past levodopa's effect. Proving a drug actually slows the disease takes hundreds of people, followed for one to two years.
The many Parkinson's problem. The genetic forms (LRRK2, GBA) behave differently from each other, and from the more common form of the disease. Some drugs might only work in one specific subtype. Newer trials are increasingly enrolling people by which gene they carry, which gives cleaner results but makes recruiting slower.
The representation problem. Parkinson's is diagnosed later, and treated less aggressively, in Black Americans, who are also underrepresented both in trials and in DBS surgery, and women are less likely than men to be referred to a specialist at all. Several current studies name diverse enrollment as a specific goal. Here's why diversity in clinical trials matters so much.
Common myths about Parkinson's
"Everyone with Parkinson's has a tremor."
Not true. About a quarter of people never develop a noticeable tremor. Stiffness, slowness, and balance problems can be the main symptoms instead, which is one reason diagnosis often gets delayed.
"Parkinson's is fatal."
Parkinson's itself isn't considered a fatal disease, and most people live for many years, often decades, after diagnosis. It's complications later on, mainly falls and pneumonia, that actually affect lifespan.
"Levodopa stops working after a few years, so delay it."
Levodopa keeps working. What changes over time is how smoothly it works as the disease advances. Studies haven't shown that delaying it protects anything, and undertreating early Parkinson's just costs quality of life. When to start it is an individual decision you make with your neurologist.
"Ozempic can treat Parkinson's."
Not according to the evidence. The Phase 3 exenatide trial came back negative, and the Parkinson's Foundation says GLP-1 drugs shouldn't be used for Parkinson's outside of research studies.
The stages of Parkinson's, and what care usually looks like
Doctors use the Hoehn and Yahr scale, from 1 (affects only one side of the body) to 5 (in a wheelchair or bed bound). Typical care: at stages 1 and 2, that's usually exercise, sometimes a dopamine agonist or MAO-B inhibitor, and levodopa once symptoms start affecting daily life. At stage 3, as balance becomes an issue, levodopa usually becomes central and timing adjustments start, and physical therapy matters more. At stages 4 and 5, pumps, deep brain stimulation, and a team approach covering swallowing, mobility, and thinking all come into play. This describes usual practice, not a recommendation, your plan belongs to you and your neurologist.
For trials, look for words like "early," "advanced with motor fluctuations," and "prodromal" in most titles, and disease slowing studies often add "within 2 years of diagnosis." Knowing your diagnosis year and stage is enough to filter through studies in minutes.
How to find a Parkinson's clinical trial
AllClinicalTrials.com lists Parkinson's studies recruiting across the US, everything from disease slowing antibodies and cell therapy to exercise, devices, and early detection. Two examples recruiting right now: the Phase 3 study of IV prasinezumab, an antibody against alpha synuclein, for people with early Parkinson's, and Slow-SPEED, which tests exercise dosage in people with early or prodromal Parkinson's.
The application takes about 5 minutes, and a family member can help you fill it out. You'll answer questions about your diagnosis year, current medicines, and stage, and if a study near you looks like a match, the research team reaches out to you. Nothing is decided until you go through informed consent, and you can stop taking part at any point. Three things to have ready: the year you were diagnosed, your current medicines and whether they wear off between doses, and your Hoehn and Yahr stage, if you know it.
Common questions
What is the best treatment for Parkinson's disease? Levodopa is still the most effective medicine, combined with regular exercise. Whether you also need other medicines, or a pump, or deep brain stimulation, depends on your stage, your symptoms, and how your medicines wear off. The best plan changes over time and gets built together with a movement disorder specialist.
What is the newest treatment for Parkinson's? Three approvals came between August 2024 and February 2025: Crexont (an extended release levodopa), Vyalev (a 24 hour levodopa pump), and Onapgo (an apomorphine pump). Tavapadon, a new once a day pill, is under FDA review going into 2026. Adaptive deep brain stimulation is the newest advance in devices.
Is there a cure for Parkinson's? No, and nothing approved slows the disease down yet. Antibodies against alpha synuclein and stem cell replacement therapy are both in Phase 3 trials, and gene targeted drugs are still in earlier stage studies. Exercise has the strongest evidence of any intervention for possibly slowing progression.
Do Parkinson's trials use a placebo? Disease slowing trials usually do, since that's the only real way to tell whether progression actually slowed, and participants keep taking their regular Parkinson's medicines throughout. Device and cell therapy trials sometimes use a sham procedure instead. Exercise and observational studies just compare different approaches, or don't use a placebo at all.
See Parkinson's clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Parkinson's Disease Clinical Trials